| Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial CM Upton, RC van Wijk, L Mockeliunas, USH Simonsson, K McHarry, ... EClinicalMedicine 48, 101414, 2022 | 88 | 2022 |
| Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude V Kantae, EHJ Krekels, A Ordas, O González, RC van Wijk, AC Harms, ... Zebrafish 13 (6), 504-510, 2016 | 77 | 2016 |
| Systems pharmacology of hepatic metabolism in zebrafish larvae RC van Wijk, EHJ Krekels, T Hankemeier, HP Spaink, PH van der Graaf Drug Discovery Today: Disease Models 22, 27-34, 2016 | 63 | 2016 |
| Mechanistic and Quantitative Understanding of Pharmacokinetics in Zebrafish Larvae through Nanoscale Blood Sampling and Metabolite Modeling of Paracetamol RC Van Wijk, EHJ Krekels, V Kantae, A Ordas, T Kreling, AC Harms, ... Journal of Pharmacology and Experimental Therapeutics 371 (1), 15-24, 2019 | 43 | 2019 |
| Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial V De Jager, N Gupte, S Nunes, GL Barnes, RC van Wijk, J Mostert, ... American Journal of Respiratory and Critical Care Medicine 205 (10), 1228-1235, 2022 | 40 | 2022 |
| Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae RC van Wijk, EHJ Krekels, V Kantae, AC Harms, T Hankemeier, ... Scientific Reports 9 (1), 2149, 2019 | 39 | 2019 |
| Integration of PKPD relationships into benefit–risk analysis F Bellanti, RC van Wijk, M Danhof, O Della Pasqua British journal of clinical pharmacology 80 (5), 979-991, 2015 | 28 | 2015 |
| Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application RC Van Wijk, USH Simonsson CPT: Pharmacometrics & Systems Pharmacology 11 (8), 991-1001, 2022 | 24 | 2022 |
| Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations RC van Wijk, R Ayoun Alsoud, H Lennernäs, USH Simonsson Applied Sciences 10 (7), 2376, 2020 | 20 | 2020 |
| Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans RC van Wijk, W Hu, SM Dijkema, DJ van den Berg, J Liu, R Bahi, ... British Journal of Pharmacology 177 (24), 5518-5533, 2020 | 19 | 2020 |
| Outside‐In Systems Pharmacology Combines Innovative Computational Methods With High‐Throughput Whole Vertebrate Studies P Schulthess, RC van Wijk, EHJ Krekels, JWT Yates, HP Spaink, ... CPT: pharmacometrics & systems pharmacology 7 (5), 285-287, 2018 | 18 | 2018 |
| Pharmacokinetic analysis across studies to drive knowledge‐integration: A tutorial on individual patient data meta‐analysis (IPDMA) RC van Wijk, MZ Imperial, RM Savic, BP Solans CPT: Pharmacometrics & Systems Pharmacology 12 (9), 1187-1200, 2023 | 14 | 2023 |
| Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs JP Ernest, JJN Goh, N Strydom, Q Wang, RC van Wijk, N Zhang, ... European Respiratory Journal 62 (2), 2023 | 14 | 2023 |
| Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat YC Wong, T Ilkova, RC van Wijk, R Hartman, ECM de Lange European Journal of Pharmaceutical Sciences 111, 514-525, 2018 | 9 | 2018 |
| Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development L Mockeliunas, A Faraj, RC Van Wijk, CM Upton, G van den Hoogen, ... Frontiers in Pharmacology 14, 1150243, 2023 | 7 | 2023 |
| Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development RC Van Wijk, AM van der Sar, EHJ Krekels, T Verboom, HP Spaink, ... Clinical and translational Science 13 (6), 1060-1064, 2020 | 7 | 2020 |
| Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy A Faraj, RC Van Wijk, L Neuman, S Desai, GE Blouse, T Knudsen, ... CPT: Pharmacometrics & Systems Pharmacology 12 (7), 977-987, 2023 | 6 | 2023 |
| Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling RC Van Wijk, L Mockeliunas, CM Upton, J Peter, AH Diacon, ... CPT: Pharmacometrics & Systems Pharmacology 12 (9), 1250-1261, 2023 | 5 | 2023 |
| Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium RC van Wijk, A Lucía, PK Sudhakar, L Sonnenkalb, C Gaudin, ... Iscience 26 (4), 2023 | 4 | 2023 |
| Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic L Mockeliunas, RC van Wijk, CM Upton, J Peter, AH Diacon, ... Vaccines 12 (3), 329, 2024 | 3 | 2024 |
Ulrika SH SimonssonUppsala UniversityVerified email at farmbio.uu.se
